Westfield Capital Management
TGTX icon

Westfield Capital Management’s TG Therapeutics TGTX Stock Holding History

Westfield Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-23,400
Closed -$445K – 259
2021
Q4 		$445K Sell
23,400
-1,643,299
-99% -$42.7M ﹤0.01% 239
2021
Q3 		$55.5M Buy
1,666,699
+27,023
+2% +$836K 0.33% 110
2021
Q2 		$63.6M Buy
+1,639,676
New +$64.4M 0.38% 99

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Westfield Capital Management's TGTX Position: Q1 2022 in Review

Westfield Capital Management sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 23,400 shares — an estimated $445K sold.

Westfield Capital Management first reported a position in TGTX in Q2 2021 and held it in 3 quarters. The position peaked at $63.6M in Q2 2021. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.

  • Westfield Capital Management reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Westfield Capital Management sold 23,400 TG Therapeutics shares in Q1 2022, an estimated $445K.
  • Westfield Capital Management first reported a position in TG Therapeutics in Q2 2021 and held it in 3 quarters.
  • Westfield Capital Management's TG Therapeutics position peaked at $63.6M in Q2 2021.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.

Based on Westfield Capital Management's 13F filing for Q1 2022, filed 16 May 2022.